No serious adverse events attributable to the intervention were reported, and all participants maintained virologic suppression throughout the study except subject R18, who discontinued ART between weeks 9 and 30, presenting with CD4 counts 230/uL, HIV RNA 5.2 log copies/mL and oral candidiasis at week 12, grade 2 diarrhea due to cryptosporidiosis at week 24 and latent syphilis at week 24. The gene discussed is CD4; the disease is cryptosporidiosis.